eMonarcHER: A Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Breast Cancer
People with High-Risk, Node-Positive, HR+, HER2+ Breast Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
• Are a male or female at least 18 years of age
• Have confirmed HR+, HER2-positive (HER2+)
• Have undergone definitive surgery of the primary breast tumor(s)
• Have high-risk disease
• Have tumor tissue from breast (preferred) or lymph node for exploratory biomarker analysis
• Have discontinued previous treatments for cancer and recovered from the acute effects of therapy
You may NOT participate in this study if you:
• Have a history of any other cancer
• Have with significant clinical cardiac abnormalities
• Have known immunodeficiency virus (HIV) infection, hepatitis B, or C
• Have any active systemic infections
• Are pregnant or breastfeeding
Contact Information
Rayhana Dhulkifl, RN, Study Coordinator
82-68 164th Street, 5th Floor, Jamaica, NY 11432
Phone: (718) 883-3797
Email: DHULKIFR@nychhc.org
21-06-415